Laurence Hicks is Director at Arch Therapeutics, Inc. (ARTH). They have made 1 open-market trade across 1 company since 2023, most recently 2023-08-31.
CIK 0001886766
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $3K since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARTH | 10,292 | — |
Shares reported on the most recent Form 4, priced at the 2023-09-08 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARTH | BUY | 2023-08-31 | 2023-09-08 | $0.28 | $3K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.